Quality Review
Meet the Q&PS Team
MedicASK Answers
MedicASK Answers Full List
Patient Safety Incident Report
Loss or theft of controlled substances
MedicASK
Files
Methoxyflurane and Opioids
Question# 987
The question has come up several times regarding multimodal pain management with Methoxy and Opiates/Ketamine. Can they be used together? Other responses have been clear as mud.
Answer:
Methoxyflurane is intended to be used as a first-line, rapid-acting analgesic for moderate to severe acute pain and should be allowed time to take effect before escalating to opioids or ketamine.
Analgesic onset typically occurs within 2–5 minutes of inhalation. The peak effect is variable and depends on patient technique and inhalation frequency, rather than a fixed time point. The duration of analgesic effect is relatively short, approximately 25–60 minutes, making methoxyflurane well suited as an initial or bridging agent and supporting a stepwise, opioid-sparing approach to pain management. Escalating to opioids before this reassessment period may result in unnecessary opioid exposure without allowing methoxyflurane to achieve its full analgesic benefit.
It is also important to remember that multimodal analgesia is not limited to methoxyflurane, opioids, and ketamine. Acetaminophen and NSAIDs, where clinically appropriate, can provide meaningful adjunctive analgesia and should continue to be considered as part of a balanced pain management strategy.
This approach is explicitly supported by the Medical Directive, which states: “Consider Analgesia Medical Directive if patient’s pain not controlled by methoxyflurane.” If pain remains inadequately controlled after methoxyflurane has had sufficient time to work, opioids or ketamine may be added as part of multimodal analgesia. When agents are combined, clinicians must recognize the additive CNS and respiratory depressant effects, use small, titrated doses, and closely monitor the patient. Methoxyflurane is not contraindicated with opioids or ketamine, but escalation should be intentional, reassessed, and clinically justified, rather than concurrent by default.
Analgesic onset typically occurs within 2–5 minutes of inhalation. The peak effect is variable and depends on patient technique and inhalation frequency, rather than a fixed time point. The duration of analgesic effect is relatively short, approximately 25–60 minutes, making methoxyflurane well suited as an initial or bridging agent and supporting a stepwise, opioid-sparing approach to pain management. Escalating to opioids before this reassessment period may result in unnecessary opioid exposure without allowing methoxyflurane to achieve its full analgesic benefit.
It is also important to remember that multimodal analgesia is not limited to methoxyflurane, opioids, and ketamine. Acetaminophen and NSAIDs, where clinically appropriate, can provide meaningful adjunctive analgesia and should continue to be considered as part of a balanced pain management strategy.
This approach is explicitly supported by the Medical Directive, which states: “Consider Analgesia Medical Directive if patient’s pain not controlled by methoxyflurane.” If pain remains inadequately controlled after methoxyflurane has had sufficient time to work, opioids or ketamine may be added as part of multimodal analgesia. When agents are combined, clinicians must recognize the additive CNS and respiratory depressant effects, use small, titrated doses, and closely monitor the patient. Methoxyflurane is not contraindicated with opioids or ketamine, but escalation should be intentional, reassessed, and clinically justified, rather than concurrent by default.